Innovative Cancer Treatment Platform Launched
Elephas Biosciences Corporation has made a significant stride in the field of cancer treatment with the introduction of the Elephas Live™ Platform. This state-of-the-art technology is designed to enhance access to immunotherapy for cancer patients, paving the way for better treatment outcomes.
Successful Initial Screening
Recently, the first cancer patient was screened using the Elephas Live Platform at inDNA Life Sciences. This marks a notable milestone in not only the company’s journey but also in the advancement of cancer care in the region. Through a strategic partnership with Sparsh Hospital, the platform is set to initiate its first international deployment, showcasing its potential.
Focus on Accuracy in Treatment Prediction
The introduction of the Elephas Live Platform is critical in addressing the challenges faced by oncologists in predicting immunotherapy response among cancer patients. The current scenario indicates that only about 20% of patients respond positively to immunotherapy. Therefore, this study aims to enhance that ratio and assist medical professionals in matching patients with suitable treatments more effectively.
Collaboration for Success
Collaboration between teams from Elephas and inDNA Life Sciences has been pivotal to the success of this implementation. Training sessions have been conducted on-site in Bhubaneswar, ensuring that the personnel involved are well-equipped to utilize this innovative approach effectively. The technology is designed to analyze clinical tissue samples collected from patients anticipated to receive immunotherapy based on their specific cancer diagnoses.
Technology Designed for Pan-Solid Tumors
The Elephas technology is engineered to evaluate treatment responses across various tumor types. This innovation aims to streamline the process for doctors and ensure that patients receive the most appropriate treatments as swiftly as possible.
Experts Emphasize the Importance of This Milestone
"Achieving this screening marks a pivotal moment for us as it validates the ability of our technology to accurately predict patient responses to existing immunotherapy treatments," stated Maneesh K. Arora, the Founder and CEO of Elephas. His acknowledgment of the collaboration with inDNA speaks volumes about the shared goal of enhancing cancer treatment.
Transformative Potential of the Collaboration
Dr. Birendranath Banerjee, the Founder & Managing Director of inDNA, expressed excitement over the partnership. He highlighted that the primary aim of this collaboration is to understand how patients from diverse geographical backgrounds and ethnicities respond to immunotherapy. This critical data will contribute greatly to optimizing treatment plans while reducing the trial-and-error approach currently prevalent in cancer therapy.
About Elephas Biosciences Corporation
Cancer remains one of the leading causes of death globally, and projections indicate that the number of affected individuals will continue to rise significantly in the coming decades. Despite the availability of numerous immunotherapy options, the effectiveness remains limited, with only 1 in 5 patients experiencing a favorable response. The Elephas Live Platform addresses this challenge by utilizing live patient biopsies to assess reactions to immunotherapies in real-time, presenting a novel solution to the problem of tumor heterogeneity.
About inDNA Life Sciences
InDNA Life Sciences is dedicated to offering precise, affordable, and reliable DNA-based diagnostic and prognostic solutions tailored to the specific needs of patients as well as clinicians. Being the first clinic focused on DNA-based diagnostics, inDNA Life Sciences aims to personalize disease management across various fields, including cancer, infertility, and cellular therapies, ultimately contributing to enhanced health outcomes.
Frequently Asked Questions
What is the Elephas Live Platform?
The Elephas Live Platform is an innovative technology that predicts immunotherapy responses in cancer patients, aiming to improve treatment outcomes.
How does this platform benefit cancer patients?
It helps clinicians accurately match patients with effective treatments, potentially increasing the positive response rate to immunotherapy.
What was the significance of the recent screening?
The screening of the first cancer patient represents a major milestone for Elephas, highlighting the platform's readiness for international application.
What challenges does the Elephas Live Platform address?
The platform addresses the low response rate to current immunotherapies by providing a more precise evaluation of how patients will respond to these treatments.
How does inDNA Life Sciences contribute to this collaboration?
inDNA Life Sciences provides a foundational partnership, facilitating the application of the Elephas technology and emphasizing the importance of geographical and ethnic variations in treatment responses.
